Gilead Sciences, Inc. which can be found using ticker (GILD) have now 26 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $119.00 and $68.50 with the average share target price sitting at $82.29. (at the time of writing). Now with the previous closing price of $79.13 and the analysts are correct then we can expect a percentage increase in value of 4.0%. Also worth taking note is the 50 day moving average now sits at $73.71 and the 200 moving average now moves to $73.24. The market capitalization for the company is 98.07B. The current share price for the company is: $78.77 USD
The potential market cap would be $101,984,127,210 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 96.06, revenue per share of $22.30 and a 11.55% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
